STAGE IV RENAL CELL CANCER AJCC V7

This early-phase study tests whether giving immunotherapy drugs (nivolumab alone or with bevacizumab or ipilimumab) before surgery is safe for people with advanced kidney cancer that has spread. About 104 participants will receive one of these treatments before their tumor is rem…

This study tested a combination of two drugs—entinostat and aldesleukin—in 47 people with kidney cancer that had spread. The goal was to see if adding entinostat could make the standard immune-boosting treatment work better. The trial looked at safety and how well the tumors shra…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking certain cell signals and a process called autophagy can slow…

This study tests whether the drug pazopanib can delay or prevent kidney cancer from returning in patients who have had all visible tumors surgically removed. About 129 adults with advanced kidney cancer that spread to other parts of the body but was fully removed by surgery will …

This study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27…

This early-phase trial tests an inhaled form of the immune-boosting drug aldesleukin (IL-2) in 70 people whose cancer has spread to the lungs. The goal is to find the safest and most effective dose, and to see if it can shrink tumors. Participants have cancers like melanoma, kidn…